Get the Stockscreener App
8.78
1.29%
-0.11
Amicus Therapeutics Inc stock is traded at $8.78, with a volume of 339.40K.
It is down -1.29% in the last 24 hours and down -8.97% over the past month.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$8.89
Open:
$8.94
24h Volume:
339.40K
Relative Volume:
0.15
Market Cap:
$2.71B
Revenue:
$493.67M
Net Income/Loss:
$-104.69M
P/E Ratio:
-25.82
EPS:
-0.34
Net Cash Flow:
$-31.51M
1W Performance:
-2.72%
1M Performance:
-8.97%
6M Performance:
-22.35%
1Y Performance:
-25.70%
1-Day Range:
$8.725
$8.94
1-Week Range:
$8.545
$9.035
52-Week Range:
$8.545
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
8.78 | 2.71B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.76 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.32 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.12 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.63 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.04 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Pompe Disease Treatment Market Size in the 7MM is expected - openPR
Amicus Therapeutics, Inc. (FOLD): Among the Stocks Under $10 With High Upside Potential - Insider Monkey
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Essex Investment Management Co. LLC - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year LowShould You Sell? - MarketBeat
Inceptionr LLC Has $130,000 Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics at Leerink Conference: Path to Profitability By Investing.com - Investing.com Canada
Amicus Therapeutics stock hits 52-week low at $8.78 By Investing.com - Investing.com Canada
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Sees Significant Drop in Short Interest - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Oppenheimer Asset Management Inc. Trims Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Principal Financial Group Inc. - Defense World
Amicus Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Amicus Therapeutics Posts Robust 2024 Financial Growth - TipRanks
Y Intercept Hong Kong Ltd Purchases 85,951 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 - GlobeNewswire
HealthInvest Partners AB Has $3.08 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
State of New Jersey Common Pension Fund D Increases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Transcend Capital Advisors LLC Buys 37,059 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Wells Fargo & Company Lowers Amicus Therapeutics (NASDAQ:FOLD) Price Target to $17.00 - MarketBeat
Needham & Company LLC Reaffirms Hold Rating for Amicus Therapeutics (NASDAQ:FOLD) - MarketBeat
Why Amicus Therapeutics, Inc. (FOLD) is the Most Oversold Pharma Stock to Buy According to Analysts - Insider Monkey
Amicus Therapeutics’ (FOLD) “Hold” Rating Reiterated at Needham & Company LLC - Defense World
Amicus Therapeutics (NASDAQ:FOLD) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Wells Fargo & Company Issues Pessimistic Forecast for Amicus Therapeutics (NASDAQ:FOLD) Stock Price - Defense World
Amicus Therapeutics files prospectus for stock sales By Investing.com - Investing.com Australia
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Call Transcript - MSN
Amicus Therapeutics CEO Campbell Bradley sells $4,000 in stock - Investing.com India
Amicus Therapeutics CEO Campbell Bradley sells $4,000 in stock By Investing.com - Investing.com Australia
Amicus Therapeutics files prospectus for stock sales - Investing.com India
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Peregrine Capital Management LLC - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Stock Quotes, Forecast and News Summary - Benzinga
Form 424B5 AMICUS THERAPEUTICS, - StreetInsider.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lifted by Rice Hall James & Associates LLC - MarketBeat
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - Yahoo Finance
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):